Legal Status of BPC-157 and TB-500 Research Peptides for Laboratory Use in the United States
Research Notice: This article covers research on TB-500 research peptide and BPC-157 research peptide — available from Palmetto Peptides for laboratory use only.
Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.
New to peptide research? Our complete guide for new laboratory researchers covers sourcing standards, purity verification, reconstitution protocols, and storage best practices for research use.
Legal Disclaimer: This article is intended for informational purposes only and does not constitute legal advice. Regulatory status of research compounds can change. Researchers and institutions should consult with appropriate legal and compliance professionals for guidance specific to their situation. Palmetto Peptides supplies BPC-157 and TB-500 exclusively for licensed laboratory research.
Last Updated: April 3, 2026
Researchers and laboratory procurement officers sourcing BPC-157 and TB-500 in the United States reasonably need to understand the regulatory and legal framework governing these compounds. The answer is nuanced — neither compound is a scheduled controlled substance at the federal level, yet neither is FDA-approved for any human or veterinary application, and the line between legal research use and illegal human use distribution is a real and important one.
This article reviews the current legal status of BPC-157 and TB-500 for laboratory research use, the relevant regulatory bodies and frameworks, what "research use only" means as a legal designation, and what regulatory developments researchers should be aware of.
Important Note: This article provides general information about the regulatory landscape as understood in April 2026. Regulatory status is subject to change. This is not legal advice. Institutions and researchers should consult legal counsel for guidance specific to their use case.
Last Updated: April 6, 2026 | Reading Time: Approximately 8 minutes | Author: Palmetto Peptides Research Team
Quick Answer
BPC-157 and TB-500 are not FDA-approved drugs, but are legally manufactured and sold under FDA Category 2 bulk substance guidance for licensed laboratory research use only -- not for human consumption.
The Relevant Regulatory Bodies
Several federal agencies have overlapping jurisdiction relevant to research peptides in the United States:
FDA (Food and Drug Administration): Regulates drugs, biologics, and medical devices. Has jurisdiction over substances intended for human or animal therapeutic use. Unapproved drugs cannot be legally sold or distributed for human use.
DEA (Drug Enforcement Administration): Administers the Controlled Substances Act (CSA). Regulates substances classified into Schedules I through V based on abuse potential and medical use. Schedule I = no accepted medical use, high abuse potential; Schedule V = low abuse potential.
FTC (Federal Trade Commission): Has jurisdiction over marketing and advertising claims. Research peptide suppliers making therapeutic or health claims in their marketing face FTC scrutiny even if the underlying FDA/DEA questions are separately addressed.
BPC-157: Current Legal Status
FDA Approval Status
BPC-157 is not approved by the FDA for any human or veterinary indication. It has been investigated in limited early-phase clinical contexts (including as PL-10 for GI conditions) but has not completed the clinical trial and regulatory review process required for FDA drug approval.
This means BPC-157 cannot legally be:
Sold as a drug for human use
Compounded by a pharmacy for human injection without navigating significant regulatory obstacles
Marketed with therapeutic health claims
Controlled Substance Status
As of April 2026, BPC-157 is not listed as a controlled substance under the federal Controlled Substances Act. It is not scheduled by the DEA. This means it does not require the same registration, record-keeping, or handling protocols as Schedule I-V substances.
Research Use Legal Framework
BPC-157 may be legally purchased and used for preclinical laboratory research by researchers operating under appropriate institutional oversight. This includes:
Academic research laboratories
Private research organizations
Contract research organizations (CROs)
Industrial R&D laboratories
The "research use only" (RUO) designation is the applicable commercial framework for this type of supply. RUO products are not approved for diagnostic or therapeutic use, and suppliers operating in this space must maintain clear separation between research supply and any human-use applications.
TB-500: Current Legal Status
TB-500 (Thymosin Beta-4 synthetic analog) is similarly not FDA-approved for any human or veterinary indication. The parent peptide, Thymosin Beta-4, has been the subject of some clinical investigation (most notably by RegeneRx Biopharmaceuticals in wound healing and cardiac indications), but no FDA-approved drug application has been completed for either Thymosin Beta-4 or the TB-500 research analog.
As of April 2026, TB-500 is not listed as a controlled substance under the Controlled Substances Act. It is not DEA-scheduled.
Same framework as BPC-157 applies: TB-500 may be purchased and used for legitimate preclinical laboratory research under appropriate institutional protocols. RUO designation governs its commercial sale.
The Compounding Question
One area of frequent confusion involves compounding pharmacies. Some compounding pharmacies have produced injectable formulations of BPC-157 and TB-500 for administration to patients — a practice that exists in a legally contested space.
The FDA has historically considered unapproved peptides like BPC-157 and TB-500 to be ineligible for compounding under the exemptions available for pharmaceutical-grade compounded drugs (under Section 503A and 503B of the FDCA). The FDA has taken enforcement actions against some compounding operations producing these compounds and has issued guidance warning about the risks of unapproved peptides.
This is a distinct regulatory situation from the RUO research supply context. Palmetto Peptides operates exclusively in the research supply space — not the pharmaceutical compounding space — and does not produce or sell injectable drug formulations for human therapeutic use.
What "Research Use Only" Means in Practice
The RUO designation is not just a disclaimer — it has real legal meaning:
What RUO means: - The product is intended for in vitro or in vivo laboratory research - The product is not approved for diagnostic, therapeutic, or other human use - The supplier is not permitted to make health claims or therapeutic implications in marketing - Purchasers are expected to be conducting legitimate laboratory research
What RUO does not mean: - That the compound has been tested and found safe for research purposes - That the compound cannot be regulated in the future - That any use by a purchaser is inherently legal — the purchaser bears responsibility for their use being legitimate research
Institutional responsibility: Research institutions (universities, research organizations) typically have their own institutional review processes for approving the use of research chemicals in their facilities. Researchers should ensure their BPC-157 or TB-500 research protocols are approved under applicable institutional guidelines.
Monitoring Regulatory Developments
The FDA has signaled growing interest in the broader research peptide and compounded peptide space. Researchers and procurement personnel sourcing these compounds for ongoing research programs should be aware that:
The FDA's position on specific compounds can change through guidance documents, warning letters, or rulemaking
State-level regulations may differ from federal regulations for some research chemicals
Import/export regulations apply if compounds are being sourced internationally or used in international collaborative research
Palmetto Peptides monitors FDA regulatory developments relevant to BPC-157, TB-500, and